Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity

This publication has 15 references indexed in Scilit:

• Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects
  Journal of Clinical Endocrinology & Metabolism, 1995
• Different Acute and Chronic Effects of Acipimox Treatment on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes
  Diabetic Medicine, 1993
• Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM
  Diabetes, 1993
• Effects of free fatty acids on somatostatin secretion, content and mRNA levels in cortical and hypothalamic fetal rat neurones in monolayer culture
  Journal of Molecular Endocrinology, 1993
• Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects
  Diabetes, 1992
• ROLE OF CHOLINERGIC MUSCARINIC PATHWAYS ON THE FREE FATTY ACID INHIBITION OF GH RESPONSES TO GHRH IN NORMAL MEN
  Clinical Endocrinology, 1990
• GROWTH HORMONE NEUROREGULATION AND ITS ALTERATIONS IN DISEASE STATES
  Clinical Endocrinology, 1988
• The Effect of Glucose and Free Fatty Acids on Growth Hormone (GH)-Releasing Factor-Mediated GH Secretion in Rats*
  Endocrinology, 1986
• Growth hormone response to propranolol and l-dopa in obese subjects
  Metabolism, 1978
• Studies on the relationship between plasma free fatty acids and growth hormone secretion in man
  Journal of Clinical Investigation, 1972